THE PATH FORWARD FOR THE HEALTH CARE INDUSTRY AT A TIME OF UNPRECEDENTED CHALLENGES
CNBC presents a virtual event featuring top health care CEOs, technologists and investors, exploring the ways the most innovative companies are addressing the coronavirus crisis, and the lasting effects the crisis will have on the industry.
From vaccines and treatments, to new tech and processes, to modeling the financial impacts and effects on legacy and upstart health care companies, Healthy Returns will feature some of the most influential voices in health care.
Led by CNBC’s anchors and reporters, Healthy Returns will hone in on the groundbreaking ideas that will help mitigate the global pandemic, and will transform the health care industry for years to come.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
PAST EVENTS: 2020 | 2019 | 2018
Watch our 2020 Event Highlights
Visit cnbc.com/healthy-returns to find in-depth coverage from the CNBC team about health care innovation.
COMING UP: Healthy Returns Spotlight – February 9, 2021
Pfizer
Albert Bourla is Chairman and CEO of Pfizer.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Epic
Judith Faulkner is Founder and CEO of Epic Systems Corporation.
The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Moderna
Stéphane Bancel is Chief Executive Officer of Moderna.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Merck
Julie Louise Gerberding is EVP and Chief Patient Officer at Merck.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.
Bristol Myers Squibb
Giovanni Caforio, M.D. is Chairman of the Board and CEO of Bristol Myers Squibb.
Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
Biomatics Capital
Julie Sunderland is Managing Director of Biomatics Capital.
Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.
Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.
Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana.
Regeneron Pharmaceuticals
Leonard Schleifer is Founder, President and CEO of Regeneron Pharmaceuticals.
Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
Verily Life Sciences
Jessica L. Mega, M.D., M.P.H, is Chief Medical Officer at Verily Life Sciences.
Jessica L. Mega, M.D., M.P.H., is the Chief Medical Officer at Verily Life Sciences. As CMO, Mega’s focus is on translating scientific insights and technological innovations into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical research efforts, including the Baseline Study.
GSK
Hal Barron is Chief Scientific Officer and President, R&D at GSK.
Hal joined GSK in January 2018 as Chief Scientific Officer and President, R&D, responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is an Executive Director of the GSK Board and a member of the Corporate Executive Team.
His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Fmr. U.S. Food and Drug Administration
Dr. Gottlieb is the former Commissioner of the U.S. Food and Drug Administration and a CNBC Contributor.
Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Komodo Health
Arif Nathoo, M.D. is Co-founder & CEO at Komodo Health.
Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.
He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.
Sanofi
John C. Reed, M.D., PhD., is EVP, Global Head of Research & Development at Sanofi.
John Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.
He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. John Reed subsequently held faculty appointments at several universities including the University of California, the University of Florida and ETH-Zurich.
In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, John Reed ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants, and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research.
John Reed has served on multiple editorial boards of research journals, and was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.
From 2013 to 2018, John Reed was Global Head of Roche Pharmaceutical Research & Early Development, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase IIb development for all therapeutic areas, overseeing R&D activities across 7 global sites.
He assumed his current position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.
BD (Becton, Dickinson and Company)
Tom Polen is CEO and President of BD (Becton, Dickinson and Company).
Tom Polen serves as chief executive officer and president of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. He also leads the BD Executive Leadership Team.
Polen joined BD in 1999, after growing an early phase start-up that was subsequently purchased by BD. From 1999 to 2004, he held a variety of sales and marketing positions with increasing responsibility, in BD Biosciences and BD Diagnostics Systems.
In 2004, Polen joined Baxter Healthcare, where he led the pharmaceutical manufacturing and services business before assuming the role of vice president of Strategic Marketing. He was later promoted to general manager of Baxter’s Injectable Pharmaceuticals business. During his tenure at Baxter, Polen was named among Chicago’s top 40 leaders under 40, by Crain’s Chicago Business.
In 2009, Polen rejoined BD as president of BD Preanalytical Systems. He assumed the role of president of BD Diagnostics Systems from 2010 to 2013, and later served as group president, responsible for BD Medical Surgical Systems and BD Pharmaceutical Systems. In 2014, Polen was named segment president, BD Medical, where he led the $12 billion acquisition of CareFusion in 2015, the company’s expansion into informatics and digital health solutions and the $24 billion acquisition of C. R. Bard, Inc. in 2017. Following the Bard acquisition, Polen was named president and chief operating officer in 2017 where he was responsible for the company’s three business segments – Medical, Life Sciences and Interventional, as well as Research and Development, Innovation, Operations and the commercial organization of the company’s Americas Region.
Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as a number of national and local associations committed to helping patients with breast cancer. He earned his bachelor’s degree from the Salisbury University of Maryland and a master’s degree in business administration from Johns Hopkins University.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
Scripps Research Translational Institute
Eric Topol is Founder and Director of the Scripps Research Translational Institute.
Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 270,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.
In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.
Sponsor Speaker
Hospital for Special Surgery
Amy Fahrenkopf, MD, MPH, is SVP and General Manager, HSS Health of Hospital for Special Surgery.
Dr. Fahrenkopf is responsible for the strategy, operations, and management of HSS Health, a digital health initiative at HSS. An executive specializing in value-based care, population health, and strategy, Dr. Fahrenkopf has held leadership positions across the healthcare industry, including Highmark Blue Cross Blue Shield, Castlight Health, and Socially Determined. In addition, she served as the Deputy Under Secretary for Health for Community Care at the Veterans Health Administration and was an Associate Principal at McKinsey & Company in their healthcare practice. A pediatrician by training, Dr. Fahrenkopf served on the medical staff at Boston Children’s Hospital and was on faculty at Harvard Medical School. Dr. Fahrenkopf earned her MD from Yale School of Medicine and her MPH from Harvard School of Public Health.
Sponsor Speaker
University of California at Berkeley
James Robinson is Leonard D. Schaeffer Professor of Health Economics and Director of BCHT at University of California at Berkeley.
James Robinson is Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. He serves on a variety of professional advisory boards and gives numerous invited speeches for pharmaceutical and technology firms, health insurance plans, hospitals, physician organizations, universities, and public agencies. At Berkeley, Professor Robinson’s research focuses on the biotechnology, medical device, insurance, and health care delivery sectors. He has published three books and over 140 papers in peer-reviewed journals such as the New England Journal of Medicine, JAMA, and Health Affairs. He teaches classes on public policy, health insurance, and the economics of the life sciences industry. In his personal life, Professor Robinson is married, has four children, participates actively in open water swimming, speaks five languages, and holds dual citizenship with the United States and France.
Sponsor Speaker
Hospital for Special Surgery
Catherine MacLean, MD, PhD, is Chief Value Medical Officer at Hospital for Special Surgery.
Catherine MacLean, MD, PhD, is the Chief Value Medical Officer at HSS where she leads the development and execution of strategies to measure, report on and improve health care value. She directs the HSS Center for the Advancement of Value in Musculoskeletal Care, which pulls together expertise from HSS and collaborating organizations to rapidly develop and deploy programs, systems and tools that will fast-track the delivery of high-value musculoskeletal care at HSS and beyond. She is a nationally recognized expert on healthcare quality and value with diverse leadership experience including strategic planning, implementation and evaluation of population health, quality and value programs. Dr. MacLean obtained her MD from Washington University, St. Louis. She completed training in internal medicine at the Harbor-UCLA Medical Center, and in rheumatology at UCLA’s Center for the Health Sciences. She obtained her PhD in health services from UCLA’s School pf Public Health.
Section 32.
Mike Pellini is Managing Partner at Section 32.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Previously, he served as CEO and Chairman of Foundation Medicine (NASDAQ:FMI), a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient (NASDAQ:CLRT), a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Thrive Earlier Detection, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Providence/St. Joseph Health).
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.
CNBC
Jim Cramer is the host of "Mad Money w/ Jim Cramer" and the co-anchor of CNBC's "Squawk on the Street."
Jim Cramer believes there is always a bull market somewhere, and he wants to help you find it. He is host of CNBC's "Mad Money," (M-F, 6PM ET) featuring lively guest interviews, viewer calls and most important, the unmatched, fiery opinions of Cramer himself. He serves as the viewer's personal guide through the confusing jungle of Wall Street investing—navigating through both opportunities and pitfalls with one goal in mind—to help them make money.
Cramer is also co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street" (M-F, 9AM-11AM ET) and the founder of TheStreet, a multimedia provider of financial commentary.
He graduated from Harvard College where he was president and editor-in-chief of the prestigious daily, The Harvard Crimson. After graduation, he became a reporter for the Tallahassee Democrat and later for the Los Angeles Herald Examiner, where he covered stories ranging from homicides to sporting events.
Cramer is a former hedge fund manager and founder/owner and senior partner of Cramer Berkowitz. His compounded rate of return was 24 percent after all fees for 14 years at Cramer Berkowitz. He retired from his hedge fund in 2001, where he finished with one of the best records in the business, including having 36 percent-plus year in 2000.
He helped Steve Brill launch American Lawyer magazine before attending Harvard Law School and earning a law degree. Upon graduating and passing the New York State Bar Examination and being admitted to the N.Y. State Bar, Cramer joined Goldman Sachs in sales and trading. While at Goldman, Cramer wrote for The New Republic about stock market issues.
In December 2013, he published the book, "Jim Cramer's Get Rich Carefully," in which he creates a guide to high-yield, low-risk investing. Cramer is also the author of "Jim Cramer's Getting Back to Even," "Stay Mad for Life: Get Rich, Stay Rich," "Mad Money: Watch TV, Get Rich," "Jim Cramer's RealMoney" and "Confessions of a Street Addict."
CNBC
Meg Tirrell is a general assignment reporter at CNBC, focusing on biotechnology and pharmaceuticals.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
CNBC
Bertha Coombs is a reporter for CNBC.
Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
CNBC
Tyler Mathisen is the co-anchor of "Power Lunch" & Vice President, Events Strategy for CNBC.
Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."
Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Pfizer
Read Bio ⟶As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Epic
Read Bio ⟶The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Moderna
Read Bio ⟶Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Merck
Read Bio ⟶Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.
Bristol Myers Squibb
Read Bio ⟶Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
Biomatics Capital
Read Bio ⟶Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.
Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.
Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana.
Regeneron Pharmaceuticals
Read Bio ⟶Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
Verily Life Sciences
Read Bio ⟶Jessica L. Mega, M.D., M.P.H., is the Chief Medical Officer at Verily Life Sciences. As CMO, Mega’s focus is on translating scientific insights and technological innovations into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical research efforts, including the Baseline Study.
GSK
Read Bio ⟶Hal joined GSK in January 2018 as Chief Scientific Officer and President, R&D, responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is an Executive Director of the GSK Board and a member of the Corporate Executive Team.
His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Fmr. U.S. Food and Drug Administration
Read Bio ⟶Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Komodo Health
Read Bio ⟶Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.
He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.
Sanofi
Read Bio ⟶John Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.
He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. John Reed subsequently held faculty appointments at several universities including the University of California, the University of Florida and ETH-Zurich.
In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, John Reed ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants, and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research.
John Reed has served on multiple editorial boards of research journals, and was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.
From 2013 to 2018, John Reed was Global Head of Roche Pharmaceutical Research & Early Development, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase IIb development for all therapeutic areas, overseeing R&D activities across 7 global sites.
He assumed his current position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.
BD (Becton, Dickinson and Company)
Read Bio ⟶Tom Polen serves as chief executive officer and president of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. He also leads the BD Executive Leadership Team.
Polen joined BD in 1999, after growing an early phase start-up that was subsequently purchased by BD. From 1999 to 2004, he held a variety of sales and marketing positions with increasing responsibility, in BD Biosciences and BD Diagnostics Systems.
In 2004, Polen joined Baxter Healthcare, where he led the pharmaceutical manufacturing and services business before assuming the role of vice president of Strategic Marketing. He was later promoted to general manager of Baxter’s Injectable Pharmaceuticals business. During his tenure at Baxter, Polen was named among Chicago’s top 40 leaders under 40, by Crain’s Chicago Business.
In 2009, Polen rejoined BD as president of BD Preanalytical Systems. He assumed the role of president of BD Diagnostics Systems from 2010 to 2013, and later served as group president, responsible for BD Medical Surgical Systems and BD Pharmaceutical Systems. In 2014, Polen was named segment president, BD Medical, where he led the $12 billion acquisition of CareFusion in 2015, the company’s expansion into informatics and digital health solutions and the $24 billion acquisition of C. R. Bard, Inc. in 2017. Following the Bard acquisition, Polen was named president and chief operating officer in 2017 where he was responsible for the company’s three business segments – Medical, Life Sciences and Interventional, as well as Research and Development, Innovation, Operations and the commercial organization of the company’s Americas Region.
Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as a number of national and local associations committed to helping patients with breast cancer. He earned his bachelor’s degree from the Salisbury University of Maryland and a master’s degree in business administration from Johns Hopkins University.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
Scripps Research Translational Institute
Read Bio ⟶Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 270,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.
In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.
Hospital for Special Surgery
Read Bio ⟶Sponsor Speaker
Sponsor Speaker
Dr. Fahrenkopf is responsible for the strategy, operations, and management of HSS Health, a digital health initiative at HSS. An executive specializing in value-based care, population health, and strategy, Dr. Fahrenkopf has held leadership positions across the healthcare industry, including Highmark Blue Cross Blue Shield, Castlight Health, and Socially Determined. In addition, she served as the Deputy Under Secretary for Health for Community Care at the Veterans Health Administration and was an Associate Principal at McKinsey & Company in their healthcare practice. A pediatrician by training, Dr. Fahrenkopf served on the medical staff at Boston Children’s Hospital and was on faculty at Harvard Medical School. Dr. Fahrenkopf earned her MD from Yale School of Medicine and her MPH from Harvard School of Public Health.
University of California at Berkeley
Read Bio ⟶Sponsor Speaker
Sponsor Speaker
James Robinson is Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. He serves on a variety of professional advisory boards and gives numerous invited speeches for pharmaceutical and technology firms, health insurance plans, hospitals, physician organizations, universities, and public agencies. At Berkeley, Professor Robinson’s research focuses on the biotechnology, medical device, insurance, and health care delivery sectors. He has published three books and over 140 papers in peer-reviewed journals such as the New England Journal of Medicine, JAMA, and Health Affairs. He teaches classes on public policy, health insurance, and the economics of the life sciences industry. In his personal life, Professor Robinson is married, has four children, participates actively in open water swimming, speaks five languages, and holds dual citizenship with the United States and France.
Hospital for Special Surgery
Read Bio ⟶Sponsor Speaker
Sponsor Speaker
Catherine MacLean, MD, PhD, is the Chief Value Medical Officer at HSS where she leads the development and execution of strategies to measure, report on and improve health care value. She directs the HSS Center for the Advancement of Value in Musculoskeletal Care, which pulls together expertise from HSS and collaborating organizations to rapidly develop and deploy programs, systems and tools that will fast-track the delivery of high-value musculoskeletal care at HSS and beyond. She is a nationally recognized expert on healthcare quality and value with diverse leadership experience including strategic planning, implementation and evaluation of population health, quality and value programs. Dr. MacLean obtained her MD from Washington University, St. Louis. She completed training in internal medicine at the Harbor-UCLA Medical Center, and in rheumatology at UCLA’s Center for the Health Sciences. She obtained her PhD in health services from UCLA’s School pf Public Health.
Section 32.
Read Bio ⟶Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Previously, he served as CEO and Chairman of Foundation Medicine (NASDAQ:FMI), a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient (NASDAQ:CLRT), a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Thrive Earlier Detection, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Providence/St. Joseph Health).
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.
CNBC
Read Bio ⟶Jim Cramer believes there is always a bull market somewhere, and he wants to help you find it. He is host of CNBC's "Mad Money," (M-F, 6PM ET) featuring lively guest interviews, viewer calls and most important, the unmatched, fiery opinions of Cramer himself. He serves as the viewer's personal guide through the confusing jungle of Wall Street investing—navigating through both opportunities and pitfalls with one goal in mind—to help them make money.
Cramer is also co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street" (M-F, 9AM-11AM ET) and the founder of TheStreet, a multimedia provider of financial commentary.
He graduated from Harvard College where he was president and editor-in-chief of the prestigious daily, The Harvard Crimson. After graduation, he became a reporter for the Tallahassee Democrat and later for the Los Angeles Herald Examiner, where he covered stories ranging from homicides to sporting events.
Cramer is a former hedge fund manager and founder/owner and senior partner of Cramer Berkowitz. His compounded rate of return was 24 percent after all fees for 14 years at Cramer Berkowitz. He retired from his hedge fund in 2001, where he finished with one of the best records in the business, including having 36 percent-plus year in 2000.
He helped Steve Brill launch American Lawyer magazine before attending Harvard Law School and earning a law degree. Upon graduating and passing the New York State Bar Examination and being admitted to the N.Y. State Bar, Cramer joined Goldman Sachs in sales and trading. While at Goldman, Cramer wrote for The New Republic about stock market issues.
In December 2013, he published the book, "Jim Cramer's Get Rich Carefully," in which he creates a guide to high-yield, low-risk investing. Cramer is also the author of "Jim Cramer's Getting Back to Even," "Stay Mad for Life: Get Rich, Stay Rich," "Mad Money: Watch TV, Get Rich," "Jim Cramer's RealMoney" and "Confessions of a Street Addict."
CNBC
Read Bio ⟶Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
CNBC
Read Bio ⟶Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
CNBC
Read Bio ⟶Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."
Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Change Healthcare is a leading independent healthcare technology company, focused on insights, innovation and accelerating the transformation of the healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
Our platform and comprehensive suite of software, analytics, technology enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.
Our Intelligent Healthcare Network is one of the largest clinical and financial healthcare networks in the U.S., facilitating over 15 billion transactions and approximately $1.5 trillion in adjudicated claims, or more than one-third of all U.S. healthcare expenditures. Our customer base includes approximately 2,400 government and commercial payer connections, 1,000,000 physicians, 125,000 dentists, 39,000 pharmacies, 6,000 hospitals and 700 laboratories.
;)
Relive some of the biggest moments from the Healthy Returns Virtual Summit
Open Video
How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
Open Video
Top health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.
Open VideoRelive some of the biggest moments from the Healthy Returns Virtual Summit
Open VideoHow innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
Open VideoTop health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.
Open Video